CG Oncology vs CRISPR Therapeutics
CG Oncology reported revenue of $4 million in fiscal 2025, about the same as CRISPR Therapeutics' $4 million in fiscal 2025. CG Oncology's revenue grew 254.7% in its latest year, and CRISPR Therapeutics' fell 90.6%. CG Oncology had an operating margin of -4722.1%, against -18933.7% at CRISPR Therapeutics. Free cash flow was −$132 million at CG Oncology and −$346 million at CRISPR Therapeutics.
Side by side
| CG Oncology | CRISPR Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $4M |
| Revenue growth | 254.7% | −90.6% |
| Revenue growth a year, last 5 years | — | 38.0% |
| Gross margin | — | — |
| Operating margin | −4,722.1% | −18,933.7% |
| Net margin | −3,985.0% | −16,569.8% |
| Free cash flow | −$132M | −$346M |
| Free cash flow margin | −3,279.2% | −9,855.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.7% | 6.6% |
| Last close | $74.40 | $42.24 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $24.8 million, sold $4.8 million | sold $14.5 million |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CG OncologyCRISPR Therapeutics
Operating margin
Percent of revenue
CG OncologyCRISPR Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CG OncologyCRISPR Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CG Oncology and CRISPR Therapeutics pages.